Sun Pharma to Present Dermatology Data at 2024 Fall Clinical Conference

Sun Pharmaceutical Industries Limited, a global leader in specialty generics, announced its participation in the 44th Annual Fall Clinical Dermatology Conference, taking place from October 24-27, 2024, in Las Vegas, Nevada. The pharmaceutical giant will unveil more than a dozen posters showcasing data from its diverse dermatology portfolio, covering treatments for alopecia areata, psoriasis, acne, and actinic keratosis.

Key highlights of the event include presentations on several of Sun Pharma’s leading dermatology products: LEQSELVI™ (deuruxolitinib), WINLEVI® (clascoterone), ILUMYA® (tildrakizumab-asmn), ODOMZO® (sonidegib), and the combination of LEVULAN® KERASTICK® (aminolevulinic acid HCl) with BLU-U® (blue light photodynamic therapy).

Dr. Marek Honczarenko, Senior Vice President and Head of Global Development at Sun Pharma, emphasized the importance of the conference as a platform to exhibit new data and underscore how the company’s innovative dermatology treatments can benefit patients with various skin conditions. Dr. Honczarenko expressed enthusiasm about engaging with the dermatology research community and industry peers.

LEQSELVI™, an oral JAK inhibitor recently approved by the U.S. Food and Drug Administration (FDA) for treating severe alopecia areata in adults, will be a focal point at the conference. Six abstracts will highlight its clinical efficacy and safety, including long-term data on scalp hair regrowth. Additionally, presentations will explore patient and clinician preferences for managing alopecia areata and optimal dosing strategies based on a Phase 2 trial.

WINLEVI® will also be prominently featured, with poster presentations revealing new findings on its impact on facial sebum levels, compatibility with other acne treatments, and efficacy and safety in patients with skin of color. Further studies will discuss its effectiveness regardless of patient age and sex and its benefits for skin moisturization and barrier integrity.

Other notable presentations include a systematic review and meta-analysis of the real-world effectiveness and safety of ILUMYA® for moderate-to-severe plaque psoriasis, a comparative analysis of ODOMZO® and vismodegib in basal cell carcinoma treatment, and the safety and efficacy of LEVULAN® KERASTICK® activated by blue light for treating facial cutaneous squamous cell carcinoma in situ.

Sun Pharma’s involvement in the conference reflects its commitment to advancing dermatological science and providing high-quality treatments for skin-related conditions. The company's diverse product portfolio and ongoing research efforts underscore its role as a key player in the global pharmaceutical landscape.